CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Operating Cash Flow
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Operating Cash Flow of $220.80 million for the 6-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-05
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-27 was $179.72M, a 12.16% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-28 was $41.08M, a 76.08% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-27 was $147.52M, a 7.43% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-27 was $213.83M, a 15.08% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net cash provided by (used in) operating activities for fiscal 2025 was $737.65M, a 0.42% increase from fiscal 2024.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net cash provided by (used in) operating activities for fiscal 2024 was $734.58M, a 7.41% increase from fiscal 2023.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net cash provided by (used in) operating activities for fiscal 2023 was $683.90M, a 10.37% increase from fiscal 2022.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. net cash provided by (used in) operating activities for fiscal 2022 was $619.64M, a 18.55% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-27 | $179.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $220.80M 10-Q · filed 2026-08-05 | $368.32M derived: sum of 3 quarters · filed 2026-08-05 | $582.15M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-28 | $41.08M 10-Q · filed 2026-05-07 | $188.60M derived: sum of 2 quarters · filed 2026-05-07 | $402.42M derived: sum of 3 quarters · filed 2026-05-07 | $607.03M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-27 | $147.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $361.35M derived: sum of 2 quarters · filed 2026-02-18 | $565.95M derived: sum of 3 quarters · filed 2026-08-05 | $737.65M 10-K · filed 2026-02-18 |
| 2025-09-27 | $213.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $418.43M derived: sum of 2 quarters · filed 2026-08-05 | $590.13M 10-Q · filed 2025-11-05 | $749.49M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-28 | $204.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $376.30M 10-Q · filed 2026-08-05 | $535.66M derived: sum of 3 quarters · filed 2026-08-05 | $787.45M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-29 | $171.70M 10-Q · filed 2026-05-07 | $331.06M derived: sum of 2 quarters · filed 2026-05-07 | $582.85M derived: sum of 3 quarters · filed 2026-05-07 | $776.39M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-28 | $159.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $411.15M derived: sum of 2 quarters · filed 2026-02-18 | $604.69M derived: sum of 3 quarters · filed 2026-02-18 | $734.58M 10-K · filed 2026-02-18 |
| 2024-09-28 | $251.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $445.33M derived: sum of 2 quarters · filed 2025-11-05 | $575.22M 10-Q · filed 2025-11-05 | $796.16M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-06-29 | $193.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $323.42M 10-Q · filed 2025-08-06 | $544.37M derived: sum of 3 quarters · filed 2026-02-18 | $749.82M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-03-30 | $129.89M 10-Q · filed 2025-05-07 | $350.83M derived: sum of 2 quarters · filed 2026-02-18 | $556.28M derived: sum of 3 quarters · filed 2026-02-18 | $704.40M derived: sum of 4 quarters · filed 2026-02-18 |
| 2023-12-30 | $220.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $426.39M derived: sum of 2 quarters · filed 2026-02-18 | $574.51M derived: sum of 3 quarters · filed 2026-02-18 | $683.90M 10-K · filed 2026-02-18 |
| 2023-09-30 | $205.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $353.57M derived: sum of 2 quarters · filed 2024-11-06 | $462.95M 10-Q · filed 2024-11-06 | $697.71M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-07-01 | $148.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $257.50M 10-Q · filed 2024-08-07 | $492.26M derived: sum of 3 quarters · filed 2025-02-19 | $625.04M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-04-01 | $109.38M 10-Q · filed 2024-05-09 | $344.14M derived: sum of 2 quarters · filed 2025-02-19 | $476.92M derived: sum of 3 quarters · filed 2025-02-19 | $626.39M derived: sum of 4 quarters · filed 2025-02-19 |
| 2022-12-31 | $234.76M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $367.54M derived: sum of 2 quarters · filed 2025-02-19 | $517.01M derived: sum of 3 quarters · filed 2025-02-19 | $619.64M 10-K · filed 2025-02-19 |
| 2022-09-24 | $132.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $282.25M derived: sum of 2 quarters · filed 2023-11-08 | $384.88M 10-Q · filed 2023-11-08 | $614.14M derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-06-25 | $149.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $252.10M 10-Q · filed 2023-08-09 | $481.36M derived: sum of 3 quarters · filed 2024-02-14 | $656.08M derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-03-26 | $102.63M 10-Q · filed 2023-05-11 | $331.89M derived: sum of 2 quarters · filed 2024-02-14 | $506.61M derived: sum of 3 quarters · filed 2024-02-14 | $693.20M derived: sum of 4 quarters · filed 2024-02-14 |
| 2021-12-25 | $229.26M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | $403.98M derived: sum of 2 quarters · filed 2024-02-14 | $590.57M derived: sum of 3 quarters · filed 2024-02-14 | $760.80M 10-K · filed 2024-02-14 |
| 2021-09-25 | $174.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $361.31M derived: sum of 2 quarters · filed 2022-11-02 | $531.54M 10-Q · filed 2022-11-02 | $669.92M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-26 | $186.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $356.82M 10-Q · filed 2022-08-03 | $495.20M derived: sum of 3 quarters · filed 2023-02-22 | $672.50M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-27 | $170.23M 10-Q · filed 2022-05-04 | $308.61M derived: sum of 2 quarters · filed 2023-02-22 | $485.91M derived: sum of 3 quarters · filed 2023-02-22 | $648.21M derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-26 | $138.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $315.68M derived: sum of 2 quarters · filed 2023-02-22 | $477.99M derived: sum of 3 quarters · filed 2023-02-22 | $546.58M 10-K · filed 2023-02-22 |
| 2020-09-26 | $177.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $339.61M derived: sum of 2 quarters · filed 2021-11-03 | $408.20M 10-Q · filed 2021-11-03 | $588.87M derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-06-27 | $162.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $230.90M 10-Q · filed 2021-08-04 | $411.57M derived: sum of 3 quarters · filed 2022-02-16 | $567.42M derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-03-28 | $68.59M 10-Q · filed 2021-05-04 | $249.27M derived: sum of 2 quarters · filed 2022-02-16 | $405.11M derived: sum of 3 quarters · filed 2022-02-16 | $534.67M derived: sum of 4 quarters · filed 2022-02-16 |
| 2019-12-28 | $180.68M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | $336.52M derived: sum of 2 quarters · filed 2022-02-16 | $466.08M derived: sum of 3 quarters · filed 2022-02-16 | $480.94M 10-K · filed 2022-02-16 |
| 2019-09-28 | $155.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $285.40M derived: sum of 2 quarters · filed 2020-10-29 | $300.26M 10-Q · filed 2020-10-29 | |
| 2019-06-29 | $129.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $144.41M 10-Q · filed 2020-08-05 | ||
| 2019-03-30 | $14.86M 10-Q · filed 2020-05-07 | |||
| 2018-12-29 | $441.14M 10-K · filed 2019-02-13 | |||
| 2018-06-30 | $123.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $183.92M 10-Q · filed 2019-07-31 | ||
| 2018-03-31 | $60.05M 10-Q · filed 2019-05-07 | |||
| 2017-12-30 | $318.07M 10-K · filed 2019-02-13 | |||
| 2016-12-31 | $316.90M 10-K · filed 2019-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |